Related Experiment Video
Updated: May 7, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.5K
Antidiabetic oils.
Ali Berraaouan1, Sanae Abid, Mohamed Bnouham
1Laboratory of Physiology and Ethnopharmacology. URAC-40, Department of Biology. Faculty of Sciences, University Mohamed Ist, Boulevard Mohamed VI; BP:717; 60 000, Oujda, Morocco. mbnouham@yahoo.fr.
Current Diabetes Reviews
|October 12, 2013
Summary
This review highlights the antidiabetic effects of various vegetable oils. These natural oils show promise in managing diabetes mellitus and its complications.
Area of Science:
- Pharmacology
- Nutrition Science
- Herbal Medicine
Background:
- Natural products, particularly plant extracts, are increasingly studied for health benefits.
- Diabetes mellitus is a significant global health concern with various treatment approaches.
- Vegetable oils represent a class of natural products with potential therapeutic applications.
Purpose of the Study:
- To review and synthesize the existing scientific literature on the antidiabetic effects of vegetable oils.
- To explore the traditional uses, pharmacological activities, and specific antidiabetic mechanisms of selected vegetable oils.
- To assess the potential of vegetable oils in preventing and managing diabetes mellitus and its complications.
Main Methods:
- A comprehensive literature search was conducted on ScienceDirect and PubMed.
- Keywords included: Diabetes mellitus, Oils, Vegetable oils, Type 1 diabetes, type 2 diabetes, antidiabetic effect, antihyperglycemic, antidiabetic oil.
- Studies focusing on experimental evidence of antidiabetic effects were compiled and analyzed.
Main Results:
- Approximately ten vegetable oils demonstrated significant antidiabetic effects in experimental studies.
- Included oils: soybean, argan, olive, palm, walnut, black cumin, safflower, Colocynth, Black seed, Rice bran, Cinnamom, and Rocket oils.
- Investigated aspects included traditional uses, pharmacological activities, and specific antidiabetic properties.
Conclusions:
- Several vegetable oils exhibit promising antidiabetic properties.
- These oils may serve as valuable natural agents for improving human health, particularly in managing diabetes mellitus.
- Further research into vegetable oils could lead to novel strategies for diabetes prevention and treatment.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
958
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
958
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
998
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
998
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K